RxDoctor Payments Data

Allison McGee, PA

Physician Assistant · Meridian, IDNPI 1467950659

Payments from drug & device makers

$3,248in general payments, 2019–2025

Across 171 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Novo Nordisk$285
  • AstraZeneca$231
  • Pfizer$206
  • Amgen$182
  • Otsuka America Pharmaceutical, Inc.$146
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$3,248100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,248 in reported general payments places this provider in the 85th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$19,321
Medicare patients
127
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol15$16,198
OzempicSemaglutide12$14,792
EliquisApixaban13$11,594
Bupropion XlBupropion Hcl12$934
ValacyclovirValacyclovir Hcl12$575
Atorvastatin Calcium52$434
Omeprazole26$429
Levothyroxine Sodium37$276
Fluticasone Propionate14$261
Amlodipine Besylate25$241
Metformin Hcl ErMetformin Hcl19$189
Rosuvastatin Calcium20$162
Albuterol Sulfate HfaAlbuterol Sulfate11$153
Losartan Potassium24$141
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$231$16,19815 claims
Novo NordiskOzempic$285$14,79212 claims
PfizerEliquis$206$11,59413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →